Salute e Benessere

Michael McDonnell, Executive Vice President and Chief Financial Officer to…

Robin Kramer, Chief Accounting Officer, to Succeed Him BiogenInc. (Nasdaq: BIIB) today announced that Michael McDonnell, Biogen's Executive Vice President and Chief Financial Officer, plans to retire from the company on February 28, 2025. Upon Mr. McDonnell's retirement, Robin Kramer, currently Chief Accounting Officer at Biogen, will assume the role of Chief Financial Officer (CFO). In the coming weeks and months, Mr. McDonnell will work closely with Ms. Kramer to ensure a smooth...
Nasdaq GlobeNewswire
28/10/2024

Lupin to focus on the development of inhalers with near-zero global warming…

Richard Dekhuijzen, em, professor of pulmonology at the Radboud university medical center in Nijmegen, the Netherland said, "The development of inhalers with near-zero global warming potential serves two major objectives: firstly, a maximal reduction of their environmental impact, and secondly, as important, keeping these medications available for those patients who really need these type of inhalers since they are unable to use dry powder inhalers." Richard Dekhuijzen, em, professor…
PR Newswire
28/10/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 28 October 2024– On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.Under the...
Nasdaq GlobeNewswire
28/10/2024

Evaxion to announce business update and third quarter 2024 financial results on…

/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2024 financial results on Thursday October 31, 2024, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 13:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and...
Nasdaq GlobeNewswire
28/10/2024

Buyback of Class B shares in Essity during week 43, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
28/10/2024

Sai Life Sciences receives EIRs from USFDA for India R&D & Manufacturing…

HYDERABAD, India, Oct.28, 2024(GLOBE NEWSWIRE) -- Sai Life Sciences, the fastest-growing IndianContract Research, Development and Manufacturing Organization (CRDMO) [1],announced that it has received Establishment Inspection Reports (EIR) from the US Food and Drug Administration (USFDA) for its R&D (Unit II, Hyderabad), and Manufacturing (Unit IV, Bidar) sites in India.The General Good Manufacturing Practices (GMP) audit was conducted at the integrated R&D campus...
Nasdaq GlobeNewswire
28/10/2024

Ottimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team…

David Epstein, Chair & Chief Executive Officer of Ottimo Pharma, said: "This new medicine is exquisitely designed and offers large potential benefits to patients across a wide range of solid tumors. It will be exciting to scale the team and deliver on the promise to patients." David Epstein, Chair & Chief Executive Officer of Ottimo Pharma, said:"This new medicine is exquisitely designed and offers large potential benefits to patients across a wide range of solid tumors…
PR Newswire
28/10/2024

NaoTrac to Redefine Surgical Navigation Robotics at MEDICA 2024

With hundreds of successful cases, NaoTrac has already been instrumental in helping surgeons save lives and enhance surgical outcomes, exemplifying Brain Navi's commitment to delivering cutting-edge medical technology solutions. With hundreds of successful cases, NaoTrac has already been instrumental in helping surgeons save lives and enhance surgical outcomes, exemplifyingBrain Navi'scommitment to delivering cutting-edge medical technology solutions. In addition to NaoTrac,Brain Navi...
PR Newswire
28/10/2024

AdJane Announces its Official Launch as a Leader in Vaccine Adjuvants

For more information about AdJane and our commitment to advancing public health please visit www.AdJane.com For more information about AdJane and our commitment to advancing public health please visitwww.AdJane.com About the company AdJane specializes in the development of vaccine adjuvants aimed at enhancing vaccine efficacy. At the heart of AdJane's innovations lies our proprietary Ada-24 adjuvant. This adjuvant has been developed through a strategic collaboration and long-term...
PR Newswire
28/10/2024

Explore Wincomm's Latest Innovations in Medical AI PCs at Medica 2024

At Medica 2024, Wincomm will unveil its next-generation medical AI PCs, featuring the latest Intel® 13th and 14th generation Core processors (Raptor Lake). These systems are engineered to deliver high-performance computing for precision medicine, offering support for Nvidia® and Intel® GPU cards. This combination provides healthcare professionals with superior computational and graphical capabilities, essential for advanced medical imaging and diagnostics. AtMedica 2024, Wincomm will unveil...
PR Newswire
28/10/2024

ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its…

ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicinesMulti-year collaboration will use ViaNautis' non-immunogenic polyNaut® nanovesicles that precisely target specific tissues and cell typesCambridge, UK, 28 October, 2024– ViaNautis Bio ("ViaNautis" or the "Company"), a groundbreaking biotechnology company at the forefront of delivering targeted genetic nanomedicines, today…
Nasdaq GlobeNewswire
28/10/2024

Philips delivers strong margin improvement; flat comparable sales due to further…

Third-quarter highlightsGroup sales amounted to EUR 4.4 billion, with flat comparable sales growthIncome from operations was EUR 337 millionAdjusted EBITA margin increased by 160 basis points from 10.2% to 11.8% of salesOperating cashflow of EUR 192 million, with a free cashflow of EUR 22 millionComparable order intake decreased by 2%, due to decline in ChinaOutlook for full-year 2024 revised to reflect deteriorated demand in China: comparable sales growth within an updated...
Nasdaq GlobeNewswire
28/10/2024

BioSenic provides third quarter 2024 Business Update

BioSenic provides third quarter 2024 Business UpdateBioSenic is actively seeking one or more new assets through a merger or acquisition process Mont-Saint-Guibert, Belgium, October 28, 2024, 7.00 am CEST – Regulated Information - BIOSENIC(Euronext Brussels and Paris: BIOS), theclinical stage company specializing in serious autoimmune and inflammatory diseases, as well as cell repair, today provides its business update for the third quarter, ended 30 September 2024...
Nasdaq GlobeNewswire
28/10/2024

/C O R R E C T I O N -- Seegene Inc./

- Preliminary results of product development automation and statistical analysis of syndromic test results powered with Microsoft's AI technology were showcased - Preliminary results of product development automation and statistical analysis of syndromic test results powered with Microsoft's AI technology were showcased - Global experts and scientists participated in building a diagnostic product development eco-system utilizing Springer Nature's scientific network - Companies...
PR Newswire
28/10/2024

Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment…

Statistically significant 68% proteinuria reduction across a broad study population, with reduction observed as early as Week 4Pegcetacoplan-treated patients showed a statistically significant and clinically meaningful 68.1% (p<0.0001) proteinuria reduction (log-transformed ratio of urine protein-to-creatinine ratio) compared to placebo, both in addition to standard of care therapy, at Week 26. The proteinuria reduction was observed as early as Week 4 and continued through the six-month…
PR Newswire
27/10/2024

Gifts & Decorations Category at the 136th Canton Fair Reflects Sustainable…

Canton Fair exhibitors embrace a sustainable and innovative festive season Canton Fair exhibitors embrace a sustainable and innovative festive season Transworld (Anshan) Inc. is a leading manufacturer and trader specializing in handicrafts, home decorations, and garden decorations. With international certifications like BSCI and FSC, the company has participated in the last 30 sessions of Canton Fair. "We are excited to introduce our latest products to global buyers at the Canton…
PR Newswire
27/10/2024

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA…

The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamabFelzartamab, an investigational anti-CD38 monoclonal antibody, is a potential first-in-class therapeutic candidate for a range of rare immune-mediated indications with planning underway for Phase 3 developmentIgA Nephropathy (IgAN) is a leading cause of chronic kidney disease with up to 40% of IgAN patients progressing...
Nasdaq GlobeNewswire
27/10/2024

Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at…

New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months 1 Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of kidney function – vs. patients' historic rapid decline 1 Fabhalta also showed a favorable safety profile with no new safety signals 1 Fabhalta is the only oral alternative complement pathway inhibitor to selectively target the underlying cause of C3G, an ultra-rare kidney...
Nasdaq GlobeNewswire
27/10/2024

Pioneering Carbon-Neutral Standards: The 136th Canton Fair Sets a New Industry…

In the spring of 2014, Canton Fair took the lead in implementing a green development plan – in only two years, the 120th Canton Fair had realized a 100 percent green booth setup. This year, Canton Fair is placing an even greater emphasis on encouraging exhibitors to use professional, environmentally friendly materials in innovative designs to further enhance the aesthetics of exhibition booths. In the spring of 2014, Canton Fair took the lead in implementing a green development plan – in only...
PR Newswire
26/10/2024

The 136th Canton Fair Highlights Product Innovation to Support a Greener Economy

Green stainless-steel products champion eco-friendly life Green stainless-steel products champion eco-friendly life Notable exhibitors include Guangdong Master Group Co., Ltd., which has developed the world's first green stainless-steel cookware with independent intellectual property rights. The product is the first of its kind to obtain the Green Product Mark certificate from TÜV Rheinland. "We need to focus on developing green products for a sustainable future," said Ou Shuhui,...
PR Newswire
26/10/2024

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of…

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024Selected for late-breaking oral presentation at ASN kidney week, the world's premier nephrology meetingResults presented show a statistically significant and clinically meaningful improvement of the prospectively defined kidney function parameter eGFR 1by 3.4mL/min/year (p<0.0001) in the varoglutamstat arm compared to placebo Results in the...
Nasdaq GlobeNewswire
26/10/2024

BIOVAXYS PROVIDES PRIVATE PLACEMENT UPDATES

The Private Placement was originally announced on July 23, 2024 (up to 10,000,000 Units for up to $500,000), and upsized on each of July 26, 2024 (up to 20,000,000 Units for up to $1,000,000), and September 20, 2024 (up to 30,000,000 Units for up to $1,500,000). Tranches of the Private Placement closed on each of July 29, 2024, August 2, 2024, September 11, 2024, September 23, 2024, and October 4, 2024. The Private Placement was originally announced onJuly 23, 2024(up to 10,000,000 Units...
PR Newswire
26/10/2024

Publication relating to transparency notifications

REGULATED INFORMATIONPublication relating to transparency notificationsMont-Saint-Guibert(Belgium), October 25, 2024 , 10:30 pm CET / 4:30 pm ET –In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.Vestal Point CapitalOn October 23, 2024, Nyxoah received a transparency notification from...
Nasdaq GlobeNewswire
25/10/2024

NeoMab Fully Human Antibody Discovery Platform: A New Flexible Mouse Purchase…

NeoMab mice utilize human V(D)J gene-encoded antibodies, exhibiting gene usage frequency and sequence diversity similar to humans, making them suitable for fully human antibody development. Their competent immune system is capable of efficiently performing antigen presentation, antibody production, and affinity maturation. The unique BALB/c genetic background and antigen presentation system enhance the ability to present antigens, with serum titers reaching 10^5 to 10^6 after 3-4 rounds of…
PR Newswire
25/10/2024
Altri  Comunicati